Short report

Conclusion of diagnostic odysseys due to inversions disrupting GLI3 and FBN1

Alistair T Pagnamenta, Jing Yu, Julie Evans, Philip Twiss, Genomics England Research Consortium, Musculoskeletal GeCIP MDT, Amaka C Offiah, Mohamed Wafik, Sarju G Mehta, Mohammed K Javaid, Sarah F Smithson, Jenny C Taylor

ABSTRACT

Many genetic testing methodologies are biased towards picking up structural variants (SVs) that alter copy number. Copy-neutral rearrangements such as inversions are therefore likely to suffer from underascertainment. In this study, manual review prompted by a virtual multidisciplinary team meeting and subsequent bioinformatic prioritisation of data from the 100K Genomes Project was performed across 43 genes linked to well-characterised skeletal disorders. Ten individuals from three independent families were found to harbour diagnostic inversions. In two families, inverted segments of 1.2/14.8 Mb unequivocally disrupted GLI3 and segregated with skeletal features consistent with Greig cephalopolysyndactyly syndrome. For one family, phenotypic blending was due to the opposing breakpoint lying ~45 kb from HOXA13. In the third family, long suspected to have Marfan syndrome, a 2.0 Mb inversion disrupting FBN1 was identified. These findings resolved lengthy diagnostic odysseys of 9–20 years and highlight the importance of direct interaction between clinicians and data-analysts. These exemplars of a rare mutational spectrum linked to these conditions extend the mutational spectra linked to these conditions.

INTRODUCTION

The rare-disease pilot phase of the 100K Genomes Project (100KGP) involved 2183 families spread across 20 different diagnostic categories. Building on previous studies, this has been a major step towards embedding whole-genome sequencing (WGS) into standard healthcare, providing valuable lessons which are being applied in the UK National Health Service (NHS) Genomic Medicine Service. One notable finding was the significant uplift in diagnostic yield made with the help of researchers, which increased the overall yield to 25%. These researcher-enabled findings included 22 non-coding variants, many of which were confirmed experimentally by splicing/luciferase studies, and several repeat expansions.

For numbered affiliations see end of article.

Correspondence to Dr Alistair T Pagnamenta, Wellcome Centre for Human Genetics, University of Oxford, Oxford, Oxfordshire, UK; listair@well.ox.ac.uk

Received 21 July 2022
Accepted 14 October 2022
Published Online First 21 November 2022

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.

To cite: Pagnamenta AT, Yu J, Evans J, et al. J Med Genet 2023;60:505–510.

Open Access

Structural variation

Published by BMJ.

Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi.org/10.1136/jmedgenet-2022-108753).

For numbered affiliations see end of article.

For numbered affiliations see end of article.

For numbered affiliations see end of article.

For numbered affiliations see end of article.
Structural variation

Library (https://doi.org/10.6084/m9.figshare.4530893.v6) and researchers can apply to access data at www.genomicsengland.co.uk/join-a-gecip-domain. If researchers discover variants that could represent a diagnosis for a participant, they are asked to submit the variants into a review/triage pipeline (online supplemental figure S1B), helping provide assurance to the Genomic Medicine Service that the diagnoses are of high quality and clinical relevance.

In the majority of rare-disease cases, DNA was extracted from blood using the EDTA method and TruSeq PCR-free high throughput library preparation was followed by 150 bp paired-read sequencing on a HiSeqX machine (Illumina). SVs were called using a combination of CANVAS and MANTA algorithms and combined into single ‘SVcf’ files. Mean sequence coverage for the 10 individuals reported here was 35–35 x and 341–519 inversions were called, consistent with the numbers seen across the 100KGP as a whole (mean 427; online supplemental table S1). Further quality control statistics are available within the Genomics England research environment.

A monthly virtual MDT meeting process was initiated to scrutinise clinical/WGS data with the aim of helping to solve unsolved musculoskeletal cases from the 100KGP. Further details describing these meetings are available in online supplemental methods. Manual review of read alignments was performed using IGV (v2.11.9), with visibility range threshold setting increased to 100kb. The SVcf file was also loaded into IGV with the feature visibility window size set to 0kb.

SVs are thought to play a significant role in dominant disease and yet are often missed by WGS analytical pipelines. We therefore sought to extend the preliminary results arising from the MDT meetings by focussing on 43 autosomal genes (online supplemental table S2) listed in the 2019 revision of the skeletal disorder nosology9 which curators at the Clinical Genome Resource (www.clinicalgenome.org) assessed as having ‘sufficient evidence’ supporting haploinsufficiency as a disease mechanism (HI=3). Gene-oriented filtering of SVs in rare disease cases from the main-programme of the 100KGP was performed with SVRare,9 as described in online supplemental methods. To validate inversions, breakpoint PCR and Sanger sequencing was performed using primers listed in online supplemental table S3.

RESULTS

Prior to the first MDT meeting, details were circulated of a boy with clinical features consistent with Greig cephalopolysyndactyly syndrome (GCS) that included relative macrocephaly, hypertelorism, postaxial polysyndactyly of hands and preaxial polysyndactyly of feet (Family 1; online supplemental figure S2). Similarly affected family members included two older siblings, the father and the paternal grandmother (figure 1A). Targeted GLI3 sequencing in 2004 and again in 2015 had been negative (online supplemental table S4). Due to a confident clinical diagnosis of GCS syndrome, manual inspection of read alignments was performed and in 4/4 affected family members clustering of split read-pairs was identified in intron 4 (figure 1B). Relative strand orientations were consistent with the presence of a 1.2 Mb inversion. This inversion had been called by Manta as chr7:42 051 297–43 254 780 (GRCh38). While the distal breakpoint disrupts GLI3, the proximal breakpoint lies within HECW1, another gene predicted to be constrained against loss of function variants (pLI=1, gnomAD 2.1.1) but not yet associated with any Mendelian disease. Breakpoints called by Manta were consistent with those seen in the Sanger validation data (online supplemental figure S3), confirming a small ~25 bp deletion at one end (online supplemental figure S4). The genuine 1.2 Mb GLI3 inversion lay within a larger 11.6 Mb inversion call. Manual scrutiny of read alignments suggested the latter to be an artefact and increased confidence for genuine inversions may be achieved by the fact that breakpoints are detected separately and represented twice in the SVcf file in a reciprocal manner (online supplemental figure S5, table S4).

As inversions are an under-reported class of SV, we sought to replicate this finding using SVRare across 71 408 rare-disease participants from 100KGP. This cohort corresponds to 33924 families, of which 5222 were recruited under the musculoskeletal domain. Here, we focussed on 43 genes linked to skeletal disorders where haploinsufficiency is a known mechanism.1 Although Manta typically calls ~400 inversions per genome, prioritisation is simpler than for deletions/duplications because only genes overlapping breakpoints are unequivocally disrupted. More detailed information of the filtering/interpretation process is provided in online supplemental figures S6 and S7.

Our systematic prioritisation uncovered Family 2, where a 14.8 Mb inversion (chr7:27 245 456–42 072 394) disrupting GLI3 was identified in 4/4 affected family members (figure 1A and B). The proband was first reviewed in the genetics clinic in her early 30s, following a termination of pregnancy due to multiple congenital abnormalities. She presented with an unusual combination of distal limb and genitourinary tract malformations. The patient was noted to have a bicornuate uterus with solitary vagina and cervix, a unilateral duplex kidney, bilateral broad and proximally placed thumbs (online supplemental figure S8A), bilateral medial displacement of the great toe (‘sandal gap’) and bilateral 2/3 toe syndactyly (online supplemental figure S8B). Clinical details for other family members are available in the online supplemental methods. Although hand-foot-genital syndrome (MIM #140000) had been suspected, targeted HOXA13 analysis and exome sequencing failed to identify any pathogenic variants. While disruption of GLI3 at the proximal breakpoint likely contributes to the skeletal phenotype, the distal breakpoint in 7p15.2 lies—45 kb upstream of HOXA13 and so positional effects may underlie the more variable urogenital anomalies. Breakpoint PCR and Sanger sequencing validated the inversion and confirmed the breakpoints to be consistent with those called by Manta (online supplemental figure S9), although with a small 14 bp insertion at the proximal end and a 6 bp deletion at the distal end (online supplemental figure S10).

Lastly, a mother-daughter duo (Family 3) with Marfan syndrome suspected for ~20 years shared a 2.0 Mb inversion (chr15:46 635 052–48 604 302) disrupting FBN1 (figure 1A,C). The daughter, first seen in the genetics clinic in her early teens, had skeletal features typical of the condition, with an increased upper segment:lower segment ratio, positive wrist and thumb signs, striae over the knees, upper legs and lower back, mild pectus excavatum and mild scoliosis. An echocardiogram showed marked aortic root dilatation. Despite previous genetic testing of FBN1 using a variety of methods (online supplemental table S4), the family remained without a diagnosis. Additional clinical details are available in online supplemental methods. Breakpoint PCR and Sanger sequencing validated the inversion in both affected family members and confirmed the breakpoints to be consistent with those called by Manta (online supplemental figures S11 and S12). Finding the molecular cause of disease in this family will have direct clinical utility as there are several relatives for whom we may now be able to provide accurate advice about their risks. Most notably, the proband’s son would be difficult to discharge without any molecular testing, as clinical
Figure 1 Pedigrees and characteristic read-alignment signatures for rare diagnostic inversions in three Families from 100KGP. (A) Pedigrees and genetic segregation. Shading in Family 1 indicates polysyndactyly of hands/feet, relative macrocephaly and suspected Greig syndrome. Shading in Family 2 indicates radial dysplasia, toe syndactyly and variable urogenital features, as detailed in online supplemental figure S13. Shading in Family 3 indicates thoracic aortic aneurysm and suspected Marfan syndrome. Clinical status of the proband’s son is unknown. *WGS data available from 100KGP. NA, genetic testing not performed. (B) Read-alignments viewed with IGV showing inversions of chr7:42,051,297–43,254,780 (Family 1) and chr7:27,245,456–42,072,394 (Family 2). Both GLI3-disrupting inversions have breakpoints in intron 4, confirming that truncation of the gene at this point is a bona fide disease mechanism. (C) Distal breakpoint of inversion (chr15:46,635,052–48,604,302) disrupting FBN1 shared by proband (upper track) and mother (middle). †Control (lower) is unrelated individual from 100KGP analysed using similar methods. GRCh38 read-alignments are coloured by pair orientation such that read-pairs where both reads map to the +ve genomic strand are highlighted in green. Read-pairs where both reads map to the –ve strand (blue) are seen on the other side of the breakpoint.
Structural variation features of Marfan syndrome are often incomplete in childhood and it can be a very variable condition even in adulthood.

DISCUSSION
In this study, a combination of MDT discussion, manual review and systematic bioinformatics filtering helped identify rare germline inversions involving GLI3 and FBN1. In family 1, the variant was found by manual assessment of a single candidate gene, prompted by an MDT meeting, highlighting the importance of having detailed phenotypic information to guide analysis. GCS is a highly recognisable condition and we recognise that for a majority of Mendelian disorders, genetic heterogeneity would make manual assessment of read alignments impractical. We therefore performed a systematic analysis of 43 genes involving 33,924 families which identified additional pathogenic inversions disrupting GLI3 and FBN1, highlighting that bioinformatic prioritisation of such variants is possible. Until now, the clinical pipeline used by Genomics England has only used SV calls from Canvas, explaining why copy-neutral changes such as these have been missed. As noted in other studies, optimisation of SV calling/prioritisation is a key area for pipeline development if the full value of clinical WGS is to be realised.

No large germline inversions have been reported for these genes previously, despite both disease-gene associations being described >30 years ago. A recent study identified 48 novel cases with causative variants in GLI3 and performed a review with 314 previously reported GLI3 variants, looking primarily for genotype-phenotype correlations—none of the variants were inversions. Searching HGMD identified two historical cases of GCS with translocation breakpoints in 7p13, which were critical to help pinpoint this disease gene, but no inversions. Literature searches on FBN1 identified a CAA>TTG variant but this could be classified as a multinucleotide substitution. This variant (NM_000138.5:c.1881_1883inv, p.Cys628Asn) was also present in ClinVar, alongside two other small inversions (c.6617–9_6617-8inv and c.1875_1876inv; p.Gly626Arg), but these are all much smaller than the three inversions reported here (1.2–14.8 Mb) and likely result from different mutational processes. Another recent study assessed >373 paediatric patients with Marfan syndrome and did not identify any inversions, although the methods used may have made detection of such variants difficult. Last, the Universal Mutation Database for FBN1 (www.umd.be/FBN1) contains information about 3,077 mutations, but there were no inversions reported.

Although for all three families described, the correct clinical diagnoses had been proposed previously, the precise genetic basis had remained unexplained for 9–20 years and so no specific diagnostic or predictive/prenatal test could be offered. In each case, although multiple genetic techniques were used prior to 100KGP recruitment (figure 2), most of these methods are unable to detect copy-neutral SVs such as inversions. The exception to this is karyotyping which had been performed only for Family 1. However, in that family, the inversion was 1.2 Mb in size and thus below the detection threshold. Another striking observation is that the respective diagnostic odysseys continued, even after the WGS data had been generated and the time between the sequencing data being available and reporting of the variants ranged from 3½ to 5½ years. This lag-time highlights the difficulty in picking up bona fide diagnostic inversions in a national clinical WGS project and the importance of understanding the limitations of the methodology employed. In such settings, a high degree of specificity is needed due to limited knowledge regarding the pathogenic importance of copy-neutral SVs.

Both GCS and Pallister-Hall syndrome (PHS) are caused by variants in GLI3. Genotype-phenotype correlation studies have indicated that mutations in the N-terminal and C-terminal thirds of the gene lead to GCS whereas mutations in the middle section lead to PHS. A later study confirmed this correlation and suggested the coordinates of the central PHS specific region to be between nucleotides 1998 and 3,481. Both inversions

Figure 2 Diagnostic odyssey timelines for Families 1–3. For Family 1, precise dates were unavailable for karyotyping and array testing. *Sequence data initially analysed in 2016 using GRCh37 as a reference. The same data were remapped and reanalysed on GRCh38 in February 2020. †Variant identified on Rare Disease Day 2021. WGS, whole-genome sequencing.
reported here for Families 1 and 2 had breakpoints in intron four and so disrupt GLI3 after cDNA position 474 and therefore these results are largely consistent with the previously reported genotype-phenotype correlation for GCS. However, for Family 1, while disruption to GLI3 is likely responsible for most of the clinical features seen in this family, we cannot rule out that HECW1 disruption could be relevant with respect to some of the atypical features. For Family 2, a degree of phenotypic blending seems highly plausible given the prior suspicion for hand-foot-genital syndrome. A study from 2016 used karyotyping/WGS to characterise a homozygous 66 Mb inversion that lies 523 kb upstream of HOXA13, found in a patient with hand-foot-genital syndrome.21 Given that studies using mouse limb cells suggest that expression of HoxA genes can be controlled by enhancer elements located 5' of the gene cluster,22 the authors suggested that the large pericentric inversion might dysregulate the spatial/temporal expression of HOXA13. Due to the large distance involved, any dysregulation would likely be less severe than for dominantly acting mutations that result in disease due to haploinsufficiency, hence leading to the recessive mode of inheritance.21 Here, the distal breakpoint of the inversion in Family 2 lies just 45 kb from HOXA13 and so could potentially have a more severe effect of gene regulation.

In summary, our work stresses the need to integrate multiple SV-calling algorithms and the importance of direct interaction between clinicians and data-analysts for cases where clinical suspicion points to a particular gene. Our identification of four unrelated families harbouring inversions disrupting well-known disease genes highlights examples of a rare mutational class that has not been prioritised by Genomics England’s pipeline. Manual review prompted by a virtual MDT meeting and subsequent bioinformatic prioritisation of data can help to conclude lengthy diagnostic odysseys for the respective families.

REFERENCES

1 Smedley D, Smith KR, Martin A, Thomas EA, McDonagh EM, Cipriani V, Ellifong JM, Arno G, Tucci A, Vandrzonovova J, Chan G, Williams HJ, Ratanak E, Tei W, Stimpus K, Ibanez K, Moutiaanias L, Wiehler M, Need A, Barnes MR, V estoletti L, Buchanan J, Wordsworth S, Ashford S, Rehmström K, Li E, Fuller G, Twiss P, Spasic-Bojovic O, Halsall S, Floto RA, Poole K, Wagner A, Mehta SG, Gurnell M, Burrows N, James R, Penkett C, Duxhurst E, Gräf S, Mapeta R, Kascnakic M, Haworth A, Savage H, Babcock M, Reese MG, Bale M, Bale E, Bousted C, Brittain H, de Burca A, Bleda M, Devereau A, Halai D, Haraldsdottir E, Hyder Z, Kasparaviciute D, Patch C, Polycronopoulos D, Matchan A, Sultana R, Ryten M, Tavares ATL, Tregidgo C, Turnbull C, Welland M, Wood S, Snow C, Williams E, Leigh S, Foulger RE, Daughtery LC, Nickolou G, Leong IUS, Wright CE, Davies J, Crichton C, Welch J, Woods K, Abuhalou L, Aurora P, Rockenhauser B, Broomefield A, Cleary MA, Lam T, Dattani M, Fottiet E, Ganasan V, Grunewald S, Campoyret-Lacassagne S, Muntoni F, Pilkinson C, Quinlinia R, Thapar N, Wallis C, Wedderburn LR, Worth A, Bueser T, Compton C, Deshpande C, Fassihi H, Haque E, Izatt L, Josifova D, Mohammed S, Robert L, Rose S, Duddy R, Sarkany R, Say G, Shaw AC, Woliczko A, Habib B, Burns G, Hunter S, Grocock RH, Humphray SJ, Robinson PN, Haendel M, Simpson MA, Banka S, Clayton-Smith J, Douguou S, Hall G, Thomas HB, O’Keefe RT, Michaelides M, Moore AT, Malicka S, Pontikos N, Brown RC, Graeb S, Moutiaanias L, Wielscher M, Need A, Barnes MR, Vestito L, Clayton SM, Baunton A, Babcock M, Wielscher M, Need A, Barnes MR.

2 Taylor JC, Martin HC, Lise S, Brotholme J, Cazier L-B, Rimmer A, Kanapin A, Lunter G, Fidday S, Allan C, Aricenous AR, Attar M, Babbs C, Beccj J, Beeson D, Bento C, Bignell P, Blair E, Buckle VJ, Bull K, Caig O, Cariho R, Chapel H, Copley RR, Cornall R, Craft J, Dahan K, Davenport EE, Devost C, Devystx P, Fenwick A, Flint J, Fugger M, Mailis M, Mboin A, Offiah C, Pagnamenta A, Sabir D, Shears S, F Smithson M, Suri J, Taylor A, Wilkie L, Wilson D.

3 Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK

4 Bristol Genetics Laboratory, North Bristol NHS Trust, Bristol, UK

5 Cambridge Genomics Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

6 Department of Clinical Genetics, Cambridge University Hospitals NHS Foundation Trust, London, UK

7 Department of Clinical Genetics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

8 Nuffield Department of Orthopaedics, Rheumatology and Orthopaedic Sciences, University of Oxford, Oxford, UK

9 Department of Clinical Genetics, University Hospitals Bristol NHS Foundation Trust, Bristol, UK

Acknowledgements This research was made possible through access to the data and findings generated by the 100,000 Genomes Project. The 100,000 Genomes Project is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The 100,000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support.

Collaborators The Genomics England Research Consortium: J J Ambrose; P Arumugam; R Bevers; M Bleda; F Boardman-Pretty; C R Boustred; H Brittain; M Broomfield A, Cleary MA, Lam T, Dattani M, Fottiet E, Ganasan V, Grunewald S, Campoyret-Lacassagne S, Muntoni F, Pilkinson C, Quinlinia R, Thapar N, Wallis C, Wedderburn LR, Worth A, Bueser T, Compton C, Deshpande C, Fassihi H, Haque E, Izatt L, Josifova D, Mohammed S, Robert L, Rose S, Duddy R, Sarkany R, Say G, Shaw AC, Woliczko A, Habib B, Burns G, Hunter S, Grocock RH, Humphray SJ, Robinson PN, Haendel M, Simpson MA, Banka S, Clayton-Smith J, Douguou S, Hall G, Thomas HB, O’Keefe RT, Michaelides M, Moore AT, Malicka S, Pontikos N, Brown RC, Graeb S, Moutiaanias L, Wielscher M, Need A, Barnes MR, Vestito L, Clayton SM, Baunton A, Babcock M, Wielscher M, Need A, Barnes MR.

Supporting information See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs

Alistair T Pagnamenta http://orcid.org/0000-0001-7334-0602

Jemmy C Taylor http://orcid.org/0000-0003-3602-5704

This study was approved by Cambridge South REC (14/EE/1112). Participants gave informed consent to participate in the study before taking part.

Competing interests None declared.

Patient consent for publication Consent obtained directly from patient(s).

Ethics approval This study involves human participants and was approved by Cambridge South REC (14/EE/1112).

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
Structural variation

L. Gilbert RD, Gorlej A, Green A, Gregor HJ, Grocock R, Gruszczyn AV, Hastings R, Hatton E, Higgs D, Hill A, Holmes C, Howard M, Hughes L, Humbug R, Johnson D, Karpe F, Kingsbury Z, Kuni U, Knight JC, Krohn J, Lambie S, Langman C, Lonie L, Luck J, McCarthy D, Mcgowan SJ, Mcmullin MF, Miller KA, Murray L, Nemeth AH, Nesbit MA, Nutt D, Omordimoye E, Otunia AB, Pagnamenta A, Patel SY, Percy M, Petousi N, Riaza P, Riet SE, Polanco-Echeverry G, Popitsch N, Powrie F, Pugh C, Quel L, Robbins PA, Robson K, Russo A, Saahg N, van Schouwenburg PA, Schuh A, Silverman E, Simmons A, Sørensen PS, Sweeney E, Taylor J, Thakker RV, Tomlinson I, Trebes A, Twigg SR, Uhlig HH, Vyas P, Vyse T, Wall SA, Watkins H, Whyte MP, Witty L, Wright B, Yau C, Buck D, Humphry S, Ratcliffe PJ, Bell JJ, Wilkie AO, Bentley D, Donnelly P, Mcvean G. Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. Nat Genet 2015;47:77–26.

3 Ahn JW, Mann K, Walsh S, Shehab M, Hoang S, Docherty Z, Mohammed S, Phillips AD, Cooper DN. The human gene mutation database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Mutat 2017;38:665–77.

3 Manterre T, Neveling K, Pebrell- Richard C, Benoist M, van der Zande G, Kater- Baats E, Ahn JW, Mann K, Walsh S, Shehab M, Hoang S, Docherty Z, Mohammed S, Mackie Pagnamenta AT, et al. J Med Genet 2023;60:505–510. doi:10.1136/jmedgenet-2022-108753

5 Turner EP, Scott RH, Thomas E, Jones L, Murugaesu N, Pretty FB, Halai D, Baple E, Offiah AC, Hall CM. The radiologic diagnosis of skeletal dysplasias: past, present and future. Pediatr Radiol 2020;50:1650–7.

9 Zhang S, Pei Z, Lei C, Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, Puffenberger EG, Yu J, Szabo A, Pagnamenta AT, Shalaby A, Giacopuzzi E, Taylor J. SVRare: discovering rare genetic disease, seen through the lens of craniosynostosis. Eur J Hum Genet 2021;29:2360–8.

11 Bonthron DT, Bale M, Ball EV, Evans K, Hayden M, Heywood S, Hussain M, Phillips AD, Cooper DN. The 100,000 Genomes Project: bringing whole genome sequencing to the NHS. BMJ 2015;352:100000 Genomes Project: Bringing whole genome sequencing to the NHS. BMJ 2015;352:539–40.

13 Szakiel HL, Hülsemann W, Holtgrew M, Abad-Perez AT, Elsner J, Schwartzmann S, Born D, Spielmann M, Mundlos S, Mensah MA. GI3 variants causing isolated polysyndactyly are not restricted to the protein’s C-terminal domain. Clin Genet 2021;100:758–65.

10 Tommerup N, Nielsen F. A familial reciprocal translocation t(3;7)(p21.1;p13) associated with the Greig polysyndactyly-craniofacial anomalies syndrome. Am J Med Genet A 1989;36:133–21.

4 Fransen E, Grahame A, Novelli G, Sanguineto F. Mutation analysis of the FBN1 gene in a cohort of patients with Marfan syndrome: a 10-year single center experience. Clin Chim Acta 2020;501:154–64.

12 Johnston JJ, Olivos-Glander I, Killoran C, Elson E, Turner JT, Peters KF, Abbott MH, Aughton DJ, Aylosworth AS, Bamshad MJ, Booth C, Curry CJ, David A, Dinulos MB, Flannery DB, Fox MA, Graham JM, Grant VR, Guttmacher AE, Hannibal MC, Henn W, Hennekem RCM, Holmes LB, Hoyne HE, Leppig KA, Lin AE, Madoe P, Manchester DK, Marcelis C, Mazanti M, McCann E, McDonald MT, Mendelsohn NJ, Moeschler JB, Moghaddam B, Neri G, Newbury-Ecob R, Pagon RA, Phillips JA, Sadler LS, Stoller JM, Tilstra D, Walch Vockley CM, Zackai EH, Zadet TM, Bruton L, Black GM, Biselkger LG, Molecular and clinical analyses of Greig cephalopolysyndactyly and Pallister-Hall syndromes: robust phenotype prediction from the type and position of GI3 mutations. Am J Hum Genet 2005;76:609–12.

10 Johnston JJ, Sapp JC, Turner JT, Arnold D, Afimos S, Aleck KA, Bocian M, Bodurtha JN, Cox GF, Curry CJ, Day R, Donnai D, Field M, Fujisawa I, Gabbett M, Gal M, Graham JM, Hedera P, Hennekem RCM, Hersch JH, Hopkin RJ, Kayeelli H, Kimball AJ, Kinnis V, Lin AE, Lynch SA, Maisenbacher M, Mansour S, McGaughran J, Mehta L, Murphy H, Raygada M, Robin NH, Rope AF, Rosenebaum KN, Schaefer GB, Shealy A, Smith W, Soller M, Sommer A, Stalker HJ, Steiner B, Stephani NJ, Tetschler B, Tomlinson I, Trebes A, Twigg SR, Van Driest SL, Willing M, Verstraeten A, Van Laer L, Lacro RV, Loeys BL, Molecular characterization and investigation of the role of genetic variation in phenotypic variability and response to treatment in a large pediatric Marfan syndrome cohort. Genet Med 2022;24:1045–53.

11 Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S, Hussain M, Phillips AD, Cooper DN. The human gene mutation database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Mutat 2017;38:665–77.

18 Muguruma T, Dings L, Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S, Hussain M, Phillips AD, Cooper DN. The human gene mutation database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Mutat 2017;38:665–77.

17 Meester JAN, Peeters S, Van Den Heuvel L, Vandeweyer G, Fransen E, Cappella E, Dietz HC, Forbes G, Gel BD, Goldentz E, Hoischen A, Schluth-Bolard C, El Khattabi L. Optical genome mapping enables constitutional chromosomal aberration detection. Am J Hum Genet 2021;108:1409–22.

20 Johnston JJ, Olivos-Glander I, Killoran C, Elson E, Turner JT, Peters KF, Abbott MH, Aughton DJ, Aylosworth AS, Bamshad MJ, Booth C, Curry CJ, David A, Dinulos MB, Flannery DB, Fox MA, Graham JM, Grant VR, Guttmacher AE, Hannibal MC, Henn W, Hennekem RCM, Holmes LB, Hoyne HE, Leppig KA, Lin AE, Madoe P, Manchester DK, Marcelis C, Mazanti M, McCann E, McDonald MT, Mendelsohn NJ, Moeschler JB, Moghaddam B, Neri G, Newbury-Ecob R, Pagon RA, Phillips JA, Sadler LS, Stoller JM, Tilstra D, Walch Vockley CM, Zackai EH, Zadet TM, Bruton L, Black GM, Biselkger LG, Molecular and clinical analyses of Greig cephalopolysyndactyly and Pallister-Hall syndromes: robust phenotype prediction from the type and position of GI3 mutations. Am J Hum Genet 2005;76:609–12.

15 Johnston JJ, Sapp JC, Turner JT, Arnold D, Afimos S, Aleck KA, Bocian M, Bodurtha JN, Cox GF, Curry CJ, Day R, Donnai D, Field M, Fujisawa I, Gabbett M, Gal M, Graham JM, Hedera P, Hennekem RCM, Hersch JH, Hopkin RJ, Kayeelli H, Kimball AJ, Kinnis V, Lin AE, Lynch SA, Maisenbacher M, Mansour S, McGaughran J, Mehta L, Murphy H, Raygada M, Robin NH, Rope AF, Rosenebaum KN, Schaefer GB, Shealy A, Smith W, Soller M, Sommer A, Stalker HJ, Steiner B, Stephani NJ, Tetschler B, Tomlinson I, Trebes A, Twigg SR, Van Driest SL, Willing M, Verstraeten A, Van Laer L, Lacro RV, Loeys BL, Molecular characterization and investigation of the role of genetic variation in phenotypic variability and response to treatment in a large pediatric Marfan syndrome cohort. Genet Med 2022;24:1045–53.

19 Johnston JJ, Olivos-Glander I, Killoran C, Elson E, Turner JT, Peters KF, Abbott MH, Aughton DJ, Aylosworth AS, Bamshad MJ, Booth C, Curry CJ, David A, Dinulos MB, Flannery DB, Fox MA, Graham JM, Grant VR, Guttmacher AE, Hannibal MC, Henn W, Hennekem RCM, Holmes LB, Hoyne HE, Leppig KA, Lin AE, Madoe P, Manchester DK, Marcelis C, Mazanti M, McCann E, McDonald MT, Mendelsohn NJ, Moeschler JB, Moghaddam B, Neri G, Newbury-Ecob R, Pagon RA, Phillips JA, Sadler LS, Stoller JM, Tilstra D, Walch Vockley CM, Zackai EH, Zadet TM, Bruton L, Black GM, Biselkger LG, Molecular and clinical analyses of Greig cephalopolysyndactyly and Pallister-Hall syndromes: robust phenotype prediction from the type and position of GI3 mutations. Am J Hum Genet 2005;76:609–12.